Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Safety & Regulatory Compliance
  • Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

Impacting People's Lives

"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.

LEARN MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.

COMPLIANCE OVERVIEW
Safety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Global Trends in R&D 2024

READ MORE

EMEA Insights

"IQVIA thought leadership with a focus on EMEA.

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • IQVIA Connected Intelligence™
  • IQVIA Healthcare-grade AI™
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Patient Experience Solutions with Apple devices
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
IQVIA AI is Healthcare-grade AI

Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.

LEARN MORE

Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
IQVIA Patient Experience Solutions with Apple devices

Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.

LEARN MORE
MAIN/Careers
Careers/
WORKING AT IQVIA

Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.

LEARN MORE
LIFE AT IQVIA

Careers, culture and everything in between. Find out what’s going on right here, right now.

LEARN MORE

WE’RE HIRING

"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.

SEARCH JOBS
MAIN/Contact Us
Contact Us/
Blog
Challenging the status quo in NASH
Mark DeLegge, Senior Medical Director and Strategy Lead, NASH Center of Excellence
Oct 11, 2018
  • Blogs
  • Challenging the status quo in NASH

By 2020 NASH will be the leading cause for liver transplantation globally. IQVIA’s NASH Center of Excellence offers solutions to accelerate the development of treatment options.

Pharma companies looking for new opportunities to develop drugs for unmet medical needs are increasingly drawn to patients with non-alcoholic steatohepatits (NASH). NASH is the severe form of non-alcoholic fatty liver disease (NAFLD), in which fat builds-up in the liver causing inflammation, fibrosis, cirrhosis and liver cancer. It is a growing medical concern in the US and abroad.

However, stratifying and referring the right patients for clinical trials is a challenge. IQVIA internal analysis shows the average rate of enrollment for NASH studies in the US and Europe is just 0.4 patients per site, per month, which translates to huge time and cost challenges.

Currently there are no treatment options beyond diet and exercise. While the exact cause of NASH isn’t clear, it is more common among people with type-2 diabetes and obesity. As the numbers of people with these conditions increase so too will the rate of patients suffering from NASH, creating heavy consequences on healthcare systems. It’s also driving multiple pharmaceutical manufacturers to pursue novel treatments for this unmet medical need. The therapeutic market for NASH is currently estimated to reach $35-40 billion by 2025, with dozens of drugs currently in development, and several already heading into phase III studies.

Unfortunately, the only definitive diagnostic tool for NASH is a liver biopsy. Other non-invasive biomarkers supporting a NASH diagnosis, such as a blood test or an MRI scan, are not conclusive enough to make a definitive diagnosis. Due to a lack of awareness and treatment options physicians are currently reluctant to pursue a painful and costly liver biopsy. This reluctance is compounded by the fact that more than half of liver biopsies performed on suspected NASH patients ultimately have negative results, according to IQVIA.

Other important factors impacting clinical trial recruitment in this area include:

  • NASH is generally an asymptomatic disease until late.
  • Patients have a lack of awareness of the disease.
  • Many physicians caring for NASH patients are unfamiliar with the disease and its consequences.

All of these challenges are converging to make NASH clinical trials uniquely difficult to deliver.

New Solutions to NASH’s challenging questions

To change the paradigm in NASH a new approach is needed. Tapping advanced analytics and innovative diagnostics to identify undiagnosed patients. Educating providers and patient advocacy groups about risk factors and warning signs. Supporting trial sites in new, more proactive ways. Embracing real-world evidence to better assess risk, and create market access and reimbursement strategies that make sense for NASH and the patients it affects.

In response, IQVIA’s NASH Center of Excellence is leveraging the IQVIA CORE™ to develop innovative data analytics and delivery models for complex clinical trial patient recruitment. Unparalleled data assets allow us to accelerate the identification and treatment of undiagnosed patients, and predictive analytics and algorithms help identify risk factors among NASH patients and define the patient recruitment funnel. Our Integrated NASH Site Network (INN ) then links patients and referral practices to the investigative sites in a seamless fashion.

IQVIA has also spent the last few years researching more innovative, non-invasive diagnostic options, including blood tests, imaging, and probes that measure the condition of the liver non-invasively using sound waves. Through collaborations with imaging and serum biomarker companies, IQVIA can predict the presence of fibrosis, steatosis (e.g., fat) and inflammation non-invasively. Advances in this space offer hope that less invasive tools will soon be approved for diagnosing NASH patients and to confirm trial participation.

Recruiting patients for NASH trials will always be challenging, but by constantly challenging the status quo, and by being creative in building the right network model, better education programs, data-driven recruiting strategies, and more innovative diagnostic tools, IQVIA is leading the way toward new solutions.

To learn more about NASH, read a recent 2-part series from IQVIA’s Senior Medical Director and Strategy Lead in the NASH Center of Excellence:

And to dive into how IQVIA is leveraging the CORE™ to develop innovative analytic and technology-driven solutions to helping customer navigate the NASH landscape (both before and after approval).

Related Blog

Blog
Winning the Evidence Race
By: Sarah Phillips

Related solutions

Therapeutic & Specialty Expertise

Specialized expertise and customized solutions across 14 therapeutic centers of excellence, including oncology, GI/NASH, pediatrics, neurology and rare diseases.

Contact Us